ClinicalTrials.gg
CompletedNCT07940374RT-QoLUpdated Nov 16, 2026

Quality of Life of Patients Treated by Radiotherapy for Breast and Prostate Carcinoma

An interventional study of Paper-based questionnaire administration and Electronic questionnaire administration in Quality of Life, Breast Cancer and Prostate Cancer, sponsored by Masaryk Memorial Cancer Institute. Completed at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Masaryk Memorial Cancer Institute · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Jan 2024, registered Oct 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 177 studies in Breast Neoplasms with a site in Czechia — 21 open to participants now, 44 under way, 31 of them phase 3. Breast Neoplasms · Czechia.

Enrollment
115th of 161
228 · median 500
Started
2024
with 5 others
No phase
9 of 177
4 open now
Registered
177th of 177
by date
Lead sponsor
5 of 177
Masaryk Memorial Cancer Institute

Among the 177 studies in Breast Neoplasms with a site in Czechia, this one is the 115th largest by enrollment of the 161 interventional ones that give a count, is one of 6 that started in 2024, is one of 9 with no phase, and was the 177th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

21 of the 177 studies in Breast Neoplasms with a site in Czechia are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Breast Neoplasms with a site in Czechia, or all of them as a file.
02

Study summary

The goal of this randomized study is to evaluate the feasibility of electronic questionnaires for assessing health-related quality of life in adults with breast or prostate cancer undergoing radiotherapy.

The main questions are:

  • Can electronic questionnaires be successfully used to collect quality-of-life information?
  • Does the mode of questionnaire administration (electronic or paper-based) affect questionnaire completion rates?
  • Do patients report their quality of life differently depending on whether they complete questionnaires electronically or on paper? The study compares electronic and paper-based questionnaire administration to assess differences in questionnaire completion and quality-of-life responses.

Participants were randomly assigned to one of two groups:

  • Electronic group: Participants received questionnaires online and could complete them using a computer, tablet, or smartphone.
  • Paper group: Participants received printed questionnaires provided by healthcare staff.

Both groups were asked to complete the same quality-of-life questionnaires at three time points: during radiotherapy planning, on the first day of radiotherapy, and on the last day of radiotherapy.

03

Conditions studied

  • Quality of Life
  • Breast Cancer
  • Prostate Cancer
  • Radiotherapy

Keywords

  • Quality of Life
  • Breast carcinoma
  • Prostate carcinoma
  • PROMs
  • ePROMs
  • radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age ≥18 years.
  • Female patients with breast cancer or male patients with prostate cancer.
  • Scheduled radiotherapy with curative intent.
  • Written . Exclusion Criteria: No additional exclusion criteria.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
228 participants (actual)

Study arms

  • Active comparator
    Paper

    Participants received printed questionnaires provided by healthcare staff.

    Other: Paper-based questionnaire administration

  • Experimental
    Electronic

    Participants received questionnaires online and could complete them using a computer, tablet, or smartphone.

    Other: Electronic questionnaire administration

Interventions

  • OtherPaper-based questionnaire administration

    Administration of printed EORTC QLQ-C30 and disease-specific HRQoL questionnaires (QLQ-BR45 or QLQ-PR25) at three predefined time points (T0, T1, and T2). Questionnaires are distributed by healthcare staff during scheduled visits, and completed responses are subsequently entered into the electronic study database.

  • OtherElectronic questionnaire administration

    Administration of EORTC QLQ-C30 and disease-specific HRQoL questionnaires (QLQ-BR45 or QLQ-PR25) through a secure web-based platform at three predefined time points (T0, T1, and T2). Participants can complete questionnaires remotely using a computer, tablet, or smartphone. Automated reminders are sent by email and/or text message, with telephone follow-up if necessary.

06

What researchers measure

Primary outcomes

  1. Questionnaire completion rate

    Proportion of participants with an available completed HRQoL assessment at each of the three scheduled time points (T0, T1, and T2), evaluated separately for electronic and paper-based questionnaire administration.

    Time frame: Baseline (T0), start of radiotherapy (T1), and end of radiotherapy (T2), approximately 6-8 weeks.

Secondary outcomes

  1. Availability of paired baseline and final HRQoL assessments

    Proportion of participants with available HRQoL assessments at both baseline (T0) and the last day of radiotherapy (T2), evaluated separately for electronic and paper-based questionnaire administration.

    Time frame: From baseline (T0) to the end of radiotherapy (T2), approximately 6-8 weeks.

  2. Availability of complete longitudinal HRQoL assessments

    Proportion of participants with available HRQoL assessments at all three scheduled time points (T0, T1, and T2), evaluated separately for electronic and paper-based questionnaire administration.

    Time frame: From baseline (T0) to the end of radiotherapy (T2), approximately 6-8 weeks.

  3. Health-related quality of life

    Health-related quality of life is assessed using the EORTC QLQ-C30 and disease-specific QLQ-BR45 (breast cancer) or QLQ-PR25 (prostate cancer) questionnaires. Scale scores range from 0 to 100, with higher scores indicating better functioning on functional and global health status scales and greater symptom burden on symptom scales. Results are evaluated separately for electronic and paper-based questionnaire administration.

    Time frame: Baseline (T0), start of radiotherapy (T1), and end of radiotherapy (T2), approximately 6-8 weeks.

07

Study locations

1 site
  • Masaryk Memorial Cancer Institute
    Brno, 602 00, Czechia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jan 2025, 12 months.

Of 2,664 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 12 months is below that.

Counting every sponsor, half of 2,774 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 16, 2026
StartActual
Jan 2, 2024
Primary completionActual
Jan 31, 2025
CompletionActual
Jan 31, 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940374
Lead sponsor
Masaryk Memorial Cancer Institute
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jan 2, 2024
Primary completion
Jan 31, 2025
Completion
Jan 31, 2025
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion